Patents Assigned to University of Genoa
  • Publication number: 20200368096
    Abstract: A comprehensive system for treatment of wrist joint proprioception. The system includes a manipulandum unit and a controller. The unit includes a base, a handle, a linkage assembly, and motors. The base supports a subject's forearm, and the handle is gripped by the palm. The linkage assembly connects the handle to the base, and establishes three DOFs. The motors are operatively connected to the linkage assembly. The controller is programmed to actuate, and receive feedback information from, each of the plurality of motors. Further, the controller is programmed to perform wrist proprioception assessment operations by actuating the plurality of motors to effectuate movement of the handle relative to the base in a prescribed manner indicative of position motion sense acuity as an objective measure of wrist proprioception functioning. The controller is optionally further programmed to perform rehabilitation training via controlled operation of the unit and a virtually reality environment.
    Type: Application
    Filed: August 14, 2020
    Publication date: November 26, 2020
    Applicants: Regents of the University of Minnesota, Nanyang Technological University, Fondazione Istituto Italiano di Tecnologia (Italian Institute of Technology), Università degli Studi di Genova (University of Genoa)
    Inventors: Lorenzo Masia, Juergen Konczak, Giulio Sandini, Leonardo Cappello
  • Patent number: 10786415
    Abstract: A comprehensive system for treatment of wrist joint proprioception. The system includes a manipulandum unit and a controller. The unit includes a base, a handle, a linkage assembly, and motors. The base supports a subject's forearm, and the handle is gripped by the palm. The linkage assembly connects the handle to the base, and establishes three DOFs. The motors are operatively connected to the linkage assembly. The controller is programmed to actuate, and receive feedback information from, each of the plurality of motors. Further, the controller is programmed to perform wrist proprioception assessment operations by actuating the plurality of motors to effectuate movement of the handle relative to the base in a prescribed manner indicative of position motion sense acuity as an objective measure of wrist proprioception functioning. The controller is optionally further programmed to perform rehabilitation training via controlled operation of the unit and a virtually reality environment.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 29, 2020
    Assignees: Regents of the University of Minnesota, Nanyang Technological University, Italian Institute of Technology, University of Genoa
    Inventors: Lorenzo Masia, Juergen Konczak, Giulio Sandini, Leonardo Cappello
  • Patent number: 8981065
    Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: March 17, 2015
    Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of Genoa
    Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
  • Patent number: 8637258
    Abstract: The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: January 28, 2014
    Assignees: Novo Nordisk A/S, University of Genoa, Innate Pharma, S.A.
    Inventors: Soren Berg Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Andreas Nicolai Reumert Wagtmann
  • Patent number: 8119775
    Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: February 21, 2012
    Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/S
    Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
  • Publication number: 20090081240
    Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
    Type: Application
    Filed: October 2, 2008
    Publication date: March 26, 2009
    Applicants: Novo Nordisk A/S, Innate Pharma, University of Genoa
    Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Spee, Michael Wilken
  • Patent number: 6080731
    Abstract: 5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthing-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: June 27, 2000
    Assignees: Biosearch Italia, S.p.A., University of Genoa
    Inventors: Antonio De Flora, Umberto Benatti, Marco Giovine